Conventional neuropsychological assessments for Alzheimer’s disease are burdensome and inaccurate at detecting mild cognitive impairment and predicting Alzheimer’s disease risk. Altoida’s Digital Neuro Signature (DNS), a longitudinal cognitive test consisting of two active digital biomarker metrics, alleviates these limitations. By comparison to conventional neuropsychological assessments, DNS results in faster evaluations (10 min vs 45–120 min), and generates higher test-retest in intraindividual assessment, as well as higher accuracy at detecting abnormal cognition. This study comparatively evaluates the performance of Altoida’s DNS and conventional neuropsychological assessments in intraindividual assessments of cognition and function by means of two semi-naturalistic observational experiments with 525 participants in laboratory and clinical settings. The results show that DNS is consistently more sensitive than conventional neuropsychological assessments at capturing longitudinal individual-level change, both with respect to intraindividual variability and dispersion (intraindividual variability across multiple tests), across three participant groups: healthy controls, mild cognitive impairment, and Alzheimer’s disease. Dispersion differences between DNS and conventional neuropsychological assessments were more pronounced with more advanced disease stages, and DNS-intraindividual variability was able to predict conversion from mild cognitive impairment to Alzheimer’s disease. These findings are instrumental for patient monitoring and management, remote clinical trial assessment, and timely interventions, and will hopefully contribute to a better understanding of Alzheimer’s disease.

Altoida Secures Funding and Research Partnership with Eisai Innovation to Accelerate Work Towards Predictive Dementia Diagnostics

WASHINGTON, D.C., July 6th, 2021 // Altoida, Inc., a pioneer in brain health and leader in the digital biomarkers space, today announced new financing from Eisai Innovation, Inc. (EII), a strategic investment subsidiary of Eisai Inc.

Altoida is working internationally to create a new standard in brain health measurement and predictive identification of neurodegenerative conditions, like Alzheimer’s disease, before the onset of symptoms and irreversible brain damage occurs. The new financing will be used to accelerate Altoida’s continued scientific research, product development, and global commercialization.

“We’re thrilled to work together with the Eisai Innovation team, and are honored to have their support as a member of our investor syndicate” said Travis Bond, CEO of Altoida, Inc. “Eisai’s deep expertise and global leadership in dementia-related diseases and neurodegenerative diseases makes them a perfect partner to accelerate Altoida’s ability to develop and deliver high-accuracy predictive brain health diagnostics in a non-invasive, cost-effective, and scalable way.”

Innovation in disease diagnosis is needed to identify patients in need of therapy earlier, and in a more convenient way for both patients and health care providers. While traditional paper-and-pencil tests to assess memory and analyze cognitive impairment (e.g., the Mini-mental State Exam [MMSE] or the Montreal Cognitive Assessment [MOCA]) are a staple of modern practice, they may lack the efficiency, sensitivity, and data analytics infrastructure to be scalable as the 21st century tool for early testing.

Rather than complete a memory test or similar questionnaire, Altoida’s users complete a 10 minute set of digital and augmented reality activities on their smartphone or tablet. The activities are designed to feel like a game and immerse the brain to assess it in its most realistic state. From these activities, Altoida collects data from the sensors in the users’ device to analyze nearly 750 proprietary digital biomarkers and provide an objective measurement of brain function across 11 unique cognitive domains.

With these personalized brain measurements, Altoida is working to use artificial intelligence to predict an individual’s risk of conversion from Mild Cognitive Impairment (MCI) to Alzhimer’s disease, years in advance of symptoms. This should enable preventative and therapeutic intervention to help delay disease onset and improve patient management and outcomes.

“For three decades, Eisai has delivered hope through innovation by bringing life-changing insights and therapies,” said Kazumasa Nagayama, Chief Strategy Officer (CSO) of Eisai Co., Ltd. “The work Altoida is doing with digital biomarkers may prove to revolutionize how we approach dementias, including Alzheimer’s disease, allowing interventions years ahead of traditional methods. We are excited to support and collaborate with a company that we hope will bring new therapy options to millions of patients and their families.”  

Altoida’s technology is 513(g)-exempt for use as a computerized cognitive assessment, but it has not been approved or cleared by the FDA for any other use.

About Altoida, Inc.

Altoida, Inc is making brain health smart and personal. Our innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is our validated brain health platform built on more than 20 years of cutting-edge scientific research. Our products are backed by peer-reviewed publications, multinational clinical trials and our expert team of scientists, clinicians and engineers. Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on Altoida, please visit and connect with us on LinkedIn and Twitter.

About Eisai, Inc.

Eisai Co., Ltd. is a leading global pharmaceutical company headquartered in Japan. Eisai’s corporate philosophy is based on the human health care (hhc) concept, which is to give first thought to patients and their families, and to increase the benefits that health care provides to them. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

Leveraging the experience gained from the development and marketing of a treatment for Alzheimer’s disease, Eisai aims to establish the “Eisai Dementia Platform.” Through this platform, Eisai plans to deliver novel benefits to those living with dementia and their families through constructing a “Dementia Ecosystem,” by collaborating with partners such as medical organizations, diagnostic development companies, research organizations, and bio-ventures in addition to private insurance agencies, finance industries, fitness clubs, automobile makers, retailers, and care facilities. For more information about Eisai Co., Ltd., please visit

About Eisai Innovation, Inc.

Eisai Innovation, Inc. (EII) is a subsidiary of Eisai Inc. It is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII contributes to our human health care (hhc) mission by prioritizing disease prevention, prediction and treatment through global investments and research collaboration.

Novel Technology Predicts Risk of Dementia

SAN FRANCISCO, CA, UNITED STATES, September 3, 2020 / — A novel technology has been shown to predict the risk of dementia 3 years ahead of onset. These findings provide a new opportunity for personalized preventive strategies.

A team of academic experts, from 24 global institutions, conducted this 40-month, multinational study across Europe and North America in memory clinics, general practitioner offices, and home environments. This study was done to validate the digital biomarker technology from ALTOIDA Inc, a brain health company. These findings were published, August 2020, in the journal: Alzheimer’s & Dementia Diagnosis, Assessment & Disease Monitoring.

Additional outcomes from this study include the ability to differentiate between people with, or without, amyloid brain pathology – and to predict a person’s rate of cognitive decline.

COVID pandemic and resulting brain health issues make this technology particularly valuable for a number of reasons. It allows consumers, families and care teams to remotely monitor cognitive function over time and track any decline. Harris Eyre MD PhD, of The PRODEO Institute states “Rates of cognitive decline in older adults are likely increasing due to a number of issues. COVID-related social and physical distancing creates more social isolation, a known risk factor for dementia. Emerging evidence indicates that the virus directly harms the brain. Finally, when a person requires ICU care and ventilator support, cognitive function is compromised because of stress, oxygen deprivation, systemic inflammation and multi-organ problems. This underscores the importance of better identification of at-risk individuals and the need to devote specialized brain health resources”.

Ioannis Tarnanas PhD, Founder and Chief Science Officer of ALTOIDA Inc, notes “ALTOIDA has the most precise identification of cognitive impairment and the early identification of an individual’s path toward cognitive impairment (e.g. Alzheimer’s Disease Dementias). Early identification is the trigger for prompt and effective mitigation. ALTOIDA’s scoring products and services enable an unmatched level of data acuity in making a quantifiable assessment of an individual’s cognitive and functional capabilities with ongoing monitoring and progression tracking.”

This peer-reviewed and published study validated ALTOIDA’s digital biomarker-based prognostic models. It characterized subjects using digital biomarkers in a longitudinal, multi-site, 40-month prospective study. A total of 496 individuals, either cognitively normal or diagnosed with Mild Cognitive Impairment, were involved in this study.

For further information, please contact ALTOIDA Inc at

Publication details
Buegler M et al (2020) Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimer’s & Dementia Diagnosis, Assessment & Disease Monitoring. Online. DOI: 10.1002/dad2.12073.

ALTOIDA Inc is a brain health technology company with a proven technology offering the most precise identification of cognitive impairment and the early identification of an individual’s path toward cognitive impairment (e.g. Alzheimer’s disease and other dementias). Early identification is the trigger for prompt and effective mitigation. ALTOIDA’s scoring products and services enable an unmatched level of data acuity in making a quantifiable assessment of an individual’s cognitive and functional capabilities with ongoing monitoring and progression tracking. ALTOIDA’s products and services are backed by peer-reviewed publications, multinational clinical trials and an expert team of scientists, clinicians and informaticists. ALTOIDA Inc is funded by M-Ventures, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on ALTOIDA, see

Mark Heinemeyer
+1 619-405-6500
email us here

Altoida’s FDA-cleared and CE Mark-approved medical device and brain health data platform detects Alzheimer’s Disease (AD) up to ten years prior to onset – with up to 94% accuracy.

Houston, TX – May 4, 2020 – Altoida Inc., a predictive digital biomarker company, today announced it has secured financing from Hikma Ventures, the venture capital arm of Hikma Pharmaceuticals PLC.

The financing comes at a time of rapid growth for Altoida, as the company’s -FDA cleared and CE Mark-approved medical device and brain health data platform is being used by researchers, patients and physicians across the globe to detect Alzheimer’s Disease (AD) up to ten years prior to onset. The additional financing will be used to further expand Altoida’s presence in the US, Japan, Europe and Brazil and follows the company’s $6.3 million Series A round that closed early 2019.

“Hikma Ventures is a highly reputable venture capital firm, and we share a common vision of putting better health within reach for millions of people across the globe,” said Dr. Richard Fischer, President & CEO of Altoida Inc. “Their investment in Altoida during these unprecedented times is a testament to their belief in the strength of our company and the value of our digital health technology. Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy.”

Altoida leverages predictive digital biomarkers to drive better clinical outcomes for brain disease. By leveraging the latest advancements in Artificial Intelligence (AI), Machine Learning (ML) and Augmented Reality (AR), Altoida collects functional and cognitive biomarkers to help detect Mild Cognitive Impairment (MCI) due to Alzheimer’s disease prior to its onset – with up to 94% accuracy. Now healthcare professionals have a novel way to objectively assess cognitive and everyday functions, in the most ecologically valid way.

Using Smart Device sensors, Altoida analyzes visuospatial and executive function during complex activities of daily living by asking patients to hide and seek virtual objects in a physical space. Altoida is able to detect “micro-errors” as both a prognostic and diagnostic digital biomarker, allowing medical professionals to detect Alzheimer’s disease in patients 62+ years old between six and ten years prior to the onset of symptoms – and before irreversible damage occurs. The company has validated its platform and methodology in more than 12 peer-reviewed journal publications and in more than 200 independent studies.

“We are excited to invest in Altoida and their digital health technology, which is helping patients and healthcare providers by reinventing digital biomarkers to drive better clinical outcomes for brain disease,” said Lana Ghanem, Managing Director of Hikma Ventures. “This is the latest example of Hikma Ventures commitment to supporting innovative companies utilizing machine learning and other cutting-edge technologies to meaningfully improve patients’ lives.”

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1/stable Moody’s and BB+/positive S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For more than 40 years, the company has been creating high-quality medicines and making them accessible to the people who need them.  Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and they use their unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives.  Hikma is committed to their customers, and the people they care for, and by thinking creatively and acting practically, they provide them with a broad range of branded and non-branded generic medicines.  Together, Hikma’s 8,400 colleagues are helping to shape a healthier world that enriches all our communities.  The company is a leading licensing partner, and through its venture capital arm, is helping bring innovative health technologies to people around the world.  For more information, please visit

About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma’s expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company.
For more information, please visit

About Altoida, Inc.
Altoida Inc. is a health technology firm that uses active digital biomarkers and cutting-edge technology in Artificial Intelligence (AI) and Augmented Reality (AR) to classify patients’ risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and drive better clinical outcomes for brain diseases. Led by an international team of esteemed neuroscientists, computer scientists and medical business professionals, the company offers an FDA-cleared and CE Mark-approved medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy. The company is privately held and supported by the current investor syndicate of M-Ventures (lead investor), GreySky Venture Partners, FYRFLY, Alpana Ventures, VI Partners. Altoida has offices in Houston, San Diego, and Lucerne, Switzerland. For more information, please visit and follow us on LinkedIn

Investor Enquiries
Hikma Ventures

Lana Ghanem
Managing Director, Hikma Ventures
+962 6 580 3100

Media Enquiries
Hikma Pharmaceuticals PLC

Steve Weiss
+1 732 720 2830/ +1 732 788 8279

David Belian
+1 732 720 2814/+1 848 254 4875

US Communications and Public Affairs

Altoida, Inc.
Emily Brady, BPR
+1 415 606 9350


Fantastic achievement for our Alzheimer's Disease Prediction Service (ADPS) “EIT Innovation Award Winner 2018”

The winner of the €50 000 EIT Innovators Award was Ioannis Tarnanas, CSO for Altoida, whose Alzheimer’s Disease Prediction Service uses an iPad and diagnostic tools to forecast with an accuracy of over 90% whether a person will develop Alzheimer’s disease within six years. It is estimated that someone in the world develops Alzheimer´s every three seconds but only around 35% of sufferers are diagnosed. Early diagnosis allows personalized treatment to improve prognosis and quality of life. “This is probably the most significant award I have received in my career to-date,” Ioannis said. “I am grateful for the recognition of the many years of hard work, determination and sacrifice required in going against the status quo and striving to achieve excellence.”

Altoida Chief Science Officer Ioannis Tarnanas to Keynote at Worldwebforum - Jan. 14, 2020

HOUSTON, Jan. 14, 2020 /PRNewswire/ — Altoida, Inc. today announced that Chief Science Officer Ioannis Tarnanas has been selected to keynote at the upcoming Worldwebforum to share how Artificial Intelligence (AI), Augmented Reality (AR) and Active Digital Biomarkers (aDM) can be applied to the early detection of Alzheimer’s Disease. Tarnanas joins an elite group of leading academics and business innovators carefully chosen to present on how they are driving radical change and finding answers to future challenges.

Congressional Healthcare Innovations Summit in Houston, TX - February 21, 2019

Our CEO Dr. Richard Fischer was honored and humbled to have had the opportunity to speak about the need of early diagnosis in Alzheimer’s Disease at the Congressional Healthcare Innovations Summit in Houston, Texas on February 21, 2019 at Rice University. The event, hosted by Texas Congressman Dan Crenshaw, brought together prominent members from industry, academia and government to showcase major technological advancements and to celebrate innovation in Houston, Texas and beyond.

Cutting Edge Apps in Medicine and Mental Fitness - May 04. 2019

Our CSO Dr. Ioannis Tarnanas who is a researcher in neurodegenerative diseases at ETH Zurich, explains how new technologies and apps can help Alzheimer’s patients and how they can be used as screening tools.  ­

Next Generation Medicine at Hirslanden Kliniken Zurich, Switzerland

Altoida – A Swiss Success Story
Eight out of ten start-ups remain financially unsuccessful – a big risk for investors

Every year, around 400 start-up companies in the medical sector come on the market. Only about 40 of them are really interesting for Investors like Arnd Kaltofen with VI Partners AG.

Finally, only about 10 percent of these companies actually get financing. One of the few start-ups that has made this step is Altoida Inc.

A stroke of luck for investment manager Arnd Kaltofen: “At Altoida I am absolutely convinced that the company has enormous potential for a major success in the market. We have therefore decided to participate in a second financing round after a start-up financing”.

This company has developed an app for the early detection of high-risk patients with Alzheimer’s disease. The doctors receive conclusions on a possible risk to their patients, including fine-motor tests that are performed on a tablet or a smartphone. This allows them to take timely preventive measures against the disease.

The clinic Hirslanden in Zurich now wants to integrate this app into a health check. Also in the US, the app is about to launch the market.

VR-Voice Meeting - Martin Conference Center at Harvard Medical School Boston, MA - February 6. 2018

Our CEO Dr. Richard Fischer was pleased to have had the opportunity to speak about our technology which uses Augmented Reality Digital Biomarkers to measure cognitive outcomes of MCI due to AD, at the VR-Voice Meeting – Martin Conference Center at Harvard Medical School Boston, MA – February 6. 2018.

Atlantic Fellow Podcast Global Brain Health Institute GBHI

Interview with our CSO Dr. Ioannis Tarnanas – The story behind the whole scientific endeavors

Altoida Inc., Houston, USA
Altoida AG, Lucerne, Switzerland

Our Terms of Service and our Privacy Policy